Accord Healthcare has announced the relaunch of Tadalafil Tablets, an FDA-approved phosphodiesterase type 5 (PDE5) inhibitor for oral administration, available in multiple dosage strengths.

Tadalafil Tablets are indicated for the treatment of Erectile Dysfunction (ED), the signs and symptoms of Benign Prostatic Hyperplasia (BPH), and the combination of ED and the signs and symptoms of BPH.

Speaking about the launch, Nuvan Dassanaike, Senior Vice President, Digital and Marketing Operations, said, "The relaunch of Tadalafil Tablets reflects Accord Healthcare's continued commitment to maintaining access to established, FDA?approved medicines across approved indications."

Tadalafil Tablets are available in four strengths: 2.5 mg, 5 mg, 10 mg, and 20 mg, providing doctors with multiple prescribing options in accordance with the approved prescribing information.